Researchers at the Ribeirão Preto Blood Center and the Center for Cell-Based Therapy in Brazil have developed a novel approach to enhance the efficacy of natural killer (NK) cells in cancer immunotherapy. By engineering the NK-92 cell line with chimeric antigen receptors (CARs) that incorporate specific costimulatory components—2B4 and DAP12—the team significantly improved the cells’ readiness to target and destroy tumor cells. This advancement holds promise for creating next-generation cancer therapies that are both more potent and precise.

The significance of this research lies in its potential to address a critical gap in optimizing CAR-NK cell therapies. While CAR-T cell therapies have made substantial strides, the mechanisms that govern NK cell activity remain less understood. The incorporation of 2B4 and DAP12 enhances the internal signaling pathways that activate NK cells, leading to a marked increase in their cytotoxic capabilities. Furthermore, the study introduces an innovative strategy involving dasatinib, a drug that temporarily suppresses NK cell activity, which surprisingly enhances their performance post-treatment. This dual approach of combining optimized signaling with pharmacological modulation could revolutionize how CAR-NK therapies are designed.

The implications of these findings are profound for the field of cancer immunotherapy. This research not only paves the way for more effective CAR-NK therapies but also suggests a new paradigm in cell-based treatments that leverages both genetic engineering and pharmacological control. As we move forward, this could significantly shorten drug development timelines and improve patient outcomes by providing more adaptable and controllable treatment options for various cancers.

Source: sciencedaily.com